Cybin (CYBN) Competitors $5.96 -0.09 (-1.41%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CYBN vs. PRME, IVA, OLMA, AQST, CMPS, CMPX, BCYC, KOD, ETON, and ARCTShould you be buying Cybin stock or one of its competitors? The main competitors of Cybin include Prime Medicine (PRME), Inventiva (IVA), Olema Pharmaceuticals (OLMA), Aquestive Therapeutics (AQST), COMPASS Pathways (CMPS), Compass Therapeutics (CMPX), Bicycle Therapeutics (BCYC), Kodiak Sciences (KOD), Eton Pharmaceuticals (ETON), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. Cybin vs. Its Competitors Prime Medicine Inventiva Olema Pharmaceuticals Aquestive Therapeutics COMPASS Pathways Compass Therapeutics Bicycle Therapeutics Kodiak Sciences Eton Pharmaceuticals Arcturus Therapeutics Cybin (NYSE:CYBN) and Prime Medicine (NASDAQ:PRME) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership. Do insiders and institutionals hold more shares of CYBN or PRME? 17.9% of Cybin shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 22.7% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher earnings & valuation, CYBN or PRME? Cybin has higher earnings, but lower revenue than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$4.60-1.29Prime Medicine$2.98M234.82-$195.88M-$1.56-3.33 Which has more risk and volatility, CYBN or PRME? Cybin has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Is CYBN or PRME more profitable? Cybin has a net margin of 0.00% compared to Prime Medicine's net margin of -4,016.83%. Cybin's return on equity of -37.58% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Prime Medicine -4,016.83%-156.16%-64.41% Does the media refer more to CYBN or PRME? In the previous week, Prime Medicine had 2 more articles in the media than Cybin. MarketBeat recorded 6 mentions for Prime Medicine and 4 mentions for Cybin. Cybin's average media sentiment score of 0.50 beat Prime Medicine's score of 0.23 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend CYBN or PRME? Cybin currently has a consensus target price of $85.00, suggesting a potential upside of 1,327.37%. Given Cybin's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cybin is more favorable than Prime Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Prime Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCybin beats Prime Medicine on 10 of the 16 factors compared between the two stocks. Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYBN vs. The Competition Export to ExcelMetricCybinPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$140.36M$869.68M$5.65B$21.32BDividend YieldN/A4.84%5.68%3.52%P/E Ratio-1.361.2175.7029.10Price / SalesN/A26.06514.0582.36Price / CashN/A17.6537.5624.47Price / Book0.556.4612.874.51Net Income-$57.88M-$5.42M$3.29B$1.00B7 Day Performance-0.75%-0.77%-0.33%-1.51%1 Month Performance-17.86%4.93%3.77%1.81%1 Year PerformanceN/A29.15%68.18%13.44% Cybin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYBNCybin2.7524 of 5 stars$5.96-1.4%$85.00+1,327.4%N/A$140.36MN/A-1.3650High Trading VolumePRMEPrime Medicine0.4629 of 5 stars$4.01-1.5%N/AN/A$547.72M$2.98M0.00N/ANews CoverageGap DownIVAInventiva3.1107 of 5 stars$5.31-5.3%$14.83+179.3%+153.2%$536.67M$9.95M0.00100Gap UpOLMAOlema Pharmaceuticals2.7822 of 5 stars$8.00+3.0%$24.00+200.0%-33.8%$533.29MN/A-4.0470AQSTAquestive Therapeutics1.9806 of 5 stars$5.14+1.8%$10.29+100.1%+7.5%$503.61M$44.13M-7.34160CMPSCOMPASS Pathways2.7454 of 5 stars$5.14-1.2%$16.29+216.8%-20.4%$498.89MN/A-2.79120Positive NewsCMPXCompass Therapeutics2.6963 of 5 stars$3.69+3.4%$13.88+276.0%+104.1%$493.67M$850K-8.2020BCYCBicycle Therapeutics3.502 of 5 stars$6.86-3.0%$22.22+223.9%-67.9%$490M$19.28M-1.95240KODKodiak Sciences2.842 of 5 stars$9.35+1.1%$11.75+25.7%+493.5%$488.60MN/A-2.4690News CoverageAnalyst ForecastGap UpETONEton Pharmaceuticals2.053 of 5 stars$17.78+0.7%$29.67+66.9%+246.6%$473.34M$58.18M-111.1320ARCTArcturus Therapeutics2.8089 of 5 stars$18.13+4.7%$50.57+178.9%-5.9%$470.32M$152.31M-8.13180Gap Down Related Companies and Tools Related Companies PRME Competitors IVA Competitors OLMA Competitors AQST Competitors CMPS Competitors CMPX Competitors BCYC Competitors KOD Competitors ETON Competitors ARCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CYBN) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYBN Stock Alerts